Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Mar 17, 2023
Date Accepted: May 9, 2024

The final, peer-reviewed published version of this preprint can be found here:

Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study

Onstwedder SM, Jansen ME, Cornel MC, Rigter T

Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study

J Med Internet Res 2024;26:e47389

DOI: 10.2196/47389

PMID: 39018558

PMCID: 11292153

Policy guidance for direct-to-consumer genetic testing services: development of a framework

  • Suzanne Maria Onstwedder; 
  • Marleen Elizabeth Jansen; 
  • Martina Cornelia Cornel; 
  • Tessel Rigter

ABSTRACT

Background:

With the online offer of commercial genetic tests, also called direct to consumer genetic tests (DTC-GTs), citizens can gain insight in their health and disease risk based on their genetic profile. DTC-GT offers often consist of a combination of various services or aspects, including: advertisement, information, DNA-analysis, and medical or lifestyle advice. Risks and benefits of DTC-GT services have been debated and studied extensively, but evidence regarding impact on individuals or society is still lacking. This leads to uncertainty among policy makers, law enforcers, and regulators on how to ensure and balance both public safety and autonomy, whose responsibility it is and what tools they have.

Objective:

This study aims to outline DTC-GT aspects that trigger policy issues and to help provide policy guidance regarding DTC-GT services.

Methods:

Potential risks and benefits of DTC-GT services for consumers and society as described in literature, including and beyond medical implications, were mapped via a systematic approach. These risks and benefits in the distinct service elements were structured into phases, following the steps that consumers take when using a DTC-GT service. Then, a checklist was designed which can offer guidance in DTC-GT policy issues. Checklist items were included about all DTC-GT service elements.

Results:

Potential risks and benefits of DTC-GT services were mapped from 134 articles, and structured into six phases. In summary these phases were called the consumer journey: 1) exposure, 2) pretest information, 3) DNA-analysis, 4) data management, 5) posttest information, 6) individual and societal impact. The checklist for evaluation of DTC-GT services consists of eight themes, covering 38 items that may raise policy issues in DTC-GT services. The themes include the following aspects: general service content, validity and quality assurance, potential data and privacy risks, scientific evidence and robustness, and quality of the provided information.

Conclusions:

Both the consumer journey and the checklist break the DTC-GT offer down into key aspects that may impact and compromise individual and public health, safety, and autonomy. The tools may help policy makers, regulators, and law enforcers to interpret, assess and act in the DTC-GT service market.


 Citation

Please cite as:

Onstwedder SM, Jansen ME, Cornel MC, Rigter T

Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study

J Med Internet Res 2024;26:e47389

DOI: 10.2196/47389

PMID: 39018558

PMCID: 11292153

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.